VALNEVA SE
Campus Bio-Ouest | 6, Rue Alain Bombard
44800 Saint-Herblain, France



Valneva Announces Availability of Documentation for its
Combined Shareholder Meeting and Provides Corporate
Update
Saint-Herblain (France), June 4, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a
specialty vaccine company (“the Company”), today announced the availability of documentation
for its Combined General Meeting (“the Meeting”) to be held on June 25, 2025 at 2:00 p.m.
CEST at the Sofitel Lyon Bellecour Hotel, 20 quai du Docteur Gailleton, 69002 Lyon (France).
The Preliminary Notice of Meeting – including the agenda, the draft resolutions proposed by the
Board of Directors, and instructions for participation and voting to the Meeting – was published
in the Bulletin des Annonces Légales Obligatoires (BALO) on May 21, 2025.
The information and preparatory documents related to this Meeting are available on Valneva’s
website via this Link.
Any shareholder wishing to receive, by mail or e-mail, Meeting documents referred to in Article
R. 22-10-23 of the French Commercial Code, may make a request until the fifth day inclusive
before the Meeting date, by contacting the Company at assemblee.generale@valneva.com.
Holders of bearer shares may exercise this right on the condition that they provide a
shareholding certificate certifying the registration of the shares in a bearer securities account
managed by an authorized financial intermediary.
Shareholders may also access the Meeting documentation at the Company’s registered office.
The Company also announced that after twenty-six years with Vivalis and Valneva, Mr. Franck
Grimaud, Chief Business Officer, and one of Valneva´s co-founders, will leave the Company on
June 25, 2025.
Thomas Lingelbach, Chief Executive Officer of Valneva, said, “It was a great pleasure to
have created Valneva together with Franck and worked with him up to now. Throughout his
tenure, Franck contributed in different capacities to the development of the Company and its
strategy, most notably its commercial vaccine business. I would like to personally thank him for
his dedication to the Company and its people and wish him a lot of success in his future
endeavors.”

About Valneva SE
We are a specialty vaccine company that develops, manufactures, and commercializes
prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly
specialized and targeted approach, applying our deep expertise across multiple vaccine
modalities, focused on providing either first-, best- or only-in-class vaccine solutions.
We have a strong track record, having advanced multiple vaccines from early R&D to approvals,
and currently market three proprietary travel vaccines.
Revenues from our growing commercial business help fuel the continued advancement of our
vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical
development, which is partnered with Pfizer, the world’s most clinically advanced Shigella
vaccine candidate, as well as vaccine candidates against the Zika virus and other global public
health threats.

Valneva Investor and Media Contacts
Laetitia Bachelot-Fontaine Joshua Drumm, Ph.D.
VP Global Communications & European Investor Relations VP Global Investor Relations
M +33 (0)6 4516 7099 M +001 917 815 4520
laetitia.bachelot-fontaine@valneva.com joshua.drumm@valneva.com

Forward-Looking Statements
This press release contains certain forward-looking statements relating to the business of
Valneva, including with respect to business partnerships, clinical trials, technology transfer,
regulatory approvals, sales and spending. In addition, even if the actual results or development
of Valneva are consistent with the forward-looking statements contained in this press release,
those results or developments of Valneva may not be sustained in the future. In some cases,
you can identify forward-looking statements by words such as “could,” “should,” “may,”
“expects,” “anticipates,” “believes,” “intends,” “estimates,” “aims,” “targets,” or similar words.
These forward-looking statements are based largely on the current expectations of Valneva as
of the date of this press release and are subject to a number of known and unknown risks and
uncertainties and other factors that may cause actual results, performance or achievements to
be materially different from any future results, performance or achievement expressed or implied
by these forward-looking statements. In particular, the expectations of Valneva could be affected
by, among other things, uncertainties and delays involved in the development and manufacture
of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays (including
in connection with changes in leadership at the national or agency level), competition in general,
currency fluctuations, the impact of global economic and political events, and the ability to obtain
or maintain patent or other proprietary intellectual property protection. Success in preclinical
studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of
these risks and uncertainties, there can be no assurance that the forward-looking statements
made in this press release will in fact be realized. Valneva is providing this information as of the
date of this press release and disclaims any intention or obligation to publicly update or revise
any forward-looking statements, whether as a result of new information, future events, or
otherwise.




2